5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability and reductive activation

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 8, 2000, Pages 797-800

  Hu, Longqin ^a   Liu, Bin ^a   Hacking, Douglas R ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' [2 (2 NITROPHENYL) 2 METHYLPROPIONYL] 2' DEOXY 5 FLOUROURIDINE; ESTERASE; FLOXURIDINE DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; DRUG ACTIVATION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; REACTION ANALYSIS; REDUCTION; STRUCTURE ANALYSIS;

BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG STABILITY; FLOXURIDINE; HUMANS; OXIDATION-REDUCTION; PRODRUGS;

EID: 0034678647     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00108-6     Document Type: Article

References (27)

1. Grem, J. L. In Cancer Chemotherapy: Principles and Practice; Chabner, B. A.; Collins, J. M., Ed.; J. B. Lippincott: Philadelphia, 1990; pp 180-224.
2. Daher, G. C.; Harris, B. E.; Diasio, R. B. In Anticancer Drugs: Antimetabolite Metabolism and Natural Anticancer Agents; Powis, G., Ed.; Pergamon: New York, 1994; pp 55-94.
3. Chabner, B. A. In Pharmacologic Principles of Cancer Treatment; Chabner, B. A., Ed.; W. B. Saunders Company: Philadelphia, 1982; pp 183-212.
4. Tercel M., Wilson W.R., Anderson R.F., Denny W.A. J. Med. Chem. 39:1996;1084.
5. Wilson, W. R. In Cancer Biology and Medicine; Waring, M. J.; Ponder, B. A. J., Ed.; Kluwer Academic: Lancaster, 1992; 3, pp 87-131.
6. Brown J.M. Cancer Res. 59:1999;5863.
7. Siim B.G., Atwell G.J., Anderson R.F., Wardman P., Pullen S.M., Wilson W.R., Denny W.A. J. Med. Chem. 40:1997;1381.
8. Pochopin N.L., Charman W.N., Stella V.J. Int. J. Pharmaceut. 121:1995;157.
9. Oliyai R., Stella V.J. Annu. Rev. Pharmacol. Toxicol. 32:1993;521.
10. Bundgaard, H. Design of Prodrugs; Elsevier: Amsterdam, 1985; p 357.
11. Shan D., Nicolaou M.G., Borchardt R.T., Wang B. J. Pharm. Sci. 86:1997;765.
12. McNeish I.A., Searle P.F., Young L.S., Kerr D.J. Adv. Drug Delivery Rev. 26:1997;173.
13. Niculescu-Duvaz I., Springer C.J. Adv. Drug Delivery Rev. 26:1997;151.
14. Senter P.D., Svensson H.P. Adv. Drug Delivery Rev. 22:1996;341.
15. Sherwood R.F. Adv. Drug Delivery Rev. 22:1996;269.
16. Springer C.J., Niculescu-Duvaz I. Adv. Drug Delivery Rev. 22:1996;351.
17. Bridgewater J., Minton N.P., Michael N.P., Knox P., Springer C., Collins M. Eur. J. Cancer. 31:1995;2362.
18. Anlezark G.M., Melton R.G., Sherwood R.F., Coles B., Friedlos F., Knox R.J. Biochem. Pharmacol. 44:1992;2289.
19. Knox R.J., Friedlos F., Sherwood R.F., Melton R.G., Anlezark G.M. Biochem. Pharmacol. 44:1992;2297.
20. Atwell G.J., Sykes B.M., O'Connor C.J., Denny W.A. J. Med. Chem. 37:1994;371.
21. Mitsunobu O. Synthesis. 1:1981;1.
22. Farquhar D., Chen R., Khan S. J. Med. Chem. 38:1995;488.
23. 8: 438.1313; found: 438.1321.
24. Berry, J. M.; Watson, C. Y.; Whish, W. J. D.; Threadgill, M. D. J. Chem. Soc., Perkin Trans. 1 1997, 1147.
25. Sykes B.M., Atwell G.J., Denny W.A., O'Connor J. J. Phys. Org. Chem. 8:1995;587.
26. Sykes, B. M.; Atwell, G. J.; Denny, W. A.; McLennan, D. J.; O'Connor, C. J. J. Chem. Soc. Perkin Trans. 2 1995, 337.
27. 12NO: 162.0919; Found: 162.0898.